A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uni Qure N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 289,500 shares of QURE stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
289,500
Previous 28,300 922.97%
Holding current value
$1.3 Million
Previous $191,000 687.96%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $1.26 Million - $1.81 Million
261,200 Added 922.97%
289,500 $1.51 Million
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $159,329 - $234,041
28,300 New
28,300 $191,000
Q2 2021

Aug 16, 2021

SELL
$29.97 - $37.17 $1.52 Million - $1.88 Million
-50,700 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$29.24 - $42.03 $1.08 Million - $1.56 Million
-37,100 Reduced 42.26%
50,700 $1.71 Million
Q4 2020

Feb 16, 2021

SELL
$35.35 - $50.67 $933,240 - $1.34 Million
-26,400 Reduced 23.12%
87,800 $3.17 Million
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $3.17 Million - $4.19 Million
88,000 Added 335.88%
114,200 $4.21 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $2.15 Million - $3.24 Million
-47,800 Reduced 64.59%
26,200 $1.18 Million
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $4.29 Million - $7.94 Million
-107,300 Reduced 59.18%
74,000 $3.51 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $297,040 - $596,960
-8,000 Reduced 4.23%
181,300 $13 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $6.33 Million - $12.3 Million
160,800 Added 564.21%
189,300 $7.45 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $1.13 Million - $1.76 Million
21,400 Added 301.41%
28,500 $2.23 Million
Q1 2019

May 15, 2019

SELL
$27.39 - $68.41 $194,469 - $485,711
-7,100 Reduced 50.0%
7,100 $424,000
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $79,800 - $118,755
-3,500 Reduced 19.77%
14,200 $409,000
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $238,000 - $344,640
-8,000 Reduced 31.13%
17,700 $644,000
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $122,976 - $223,664
5,600 Added 27.86%
25,700 $971,000
Q1 2018

May 15, 2018

SELL
$17.1 - $26.61 $71,820 - $111,762
-4,200 Reduced 17.28%
20,100 $472,000
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $230,121 - $476,037
24,300
24,300 $476,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $209M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.